Cargando…

OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition

BACKGROUND: Hormone receptor status in human breast cancer cells is a strong indicator of the aggressiveness of a tumor. Triple negative breast cancers (TNBC) are aggressive, difficult to treat, and contribute to high incidences of metastasis by possessing characteristics such as increased tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Covert, Hunter, Mellor, Liliana F, Wolf, Cody L, Ankenbrandt, Nicole, Emathinger, Jacqueline M, Tawara, Ken, Oxford, Julie Thom, Jorcyk, Cheryl L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700398/
https://www.ncbi.nlm.nih.gov/pubmed/31496817
http://dx.doi.org/10.2147/CMAR.S208721
_version_ 1783444865282998272
author Covert, Hunter
Mellor, Liliana F
Wolf, Cody L
Ankenbrandt, Nicole
Emathinger, Jacqueline M
Tawara, Ken
Oxford, Julie Thom
Jorcyk, Cheryl L
author_facet Covert, Hunter
Mellor, Liliana F
Wolf, Cody L
Ankenbrandt, Nicole
Emathinger, Jacqueline M
Tawara, Ken
Oxford, Julie Thom
Jorcyk, Cheryl L
author_sort Covert, Hunter
collection PubMed
description BACKGROUND: Hormone receptor status in human breast cancer cells is a strong indicator of the aggressiveness of a tumor. Triple negative breast cancers (TNBC) are aggressive, difficult to treat, and contribute to high incidences of metastasis by possessing characteristics such as increased tumor cell migration and a large presence of the transmembrane protein, cluster of differentiation 44 (CD44) on the cell membrane. Estrogen receptor-positive (ER+) cells are less aggressive and do not migrate until undergoing an epithelial-mesenchymal transition (EMT). METHODS: The relationship between EMT and CD44 during metastatic events is assessed by observing changes in EMT markers, tumor cell detachment, and migration following cytokine treatment on both parental and CD44 knockdown human breast tumor cells. RESULTS: ER+ T47D and MCF-7 human breast cancer cells treated with OSM demonstrate increased CD44 expression and CD44 cleavage. Conversely, ER- MDA-MB-231 human breast cancer cells do not show a change in CD44 expression nor undergo EMT in the presence of OSM. In ER+ cells, knockdown expression of CD44 by shRNA did not prevent EMT but did change metastatic processes such as cellular detachment and migration. OSM-induced migration was decreased in both ER+ and ER- cells with shCD44 cells compared to control cells, while the promotion of tumor cell detachment by OSM was decreased in ER+ MCF7-shCD44 cells, as compared to control cells. Interestingly, OSM-induced detachment in ER- MDA-MB-231-shCD44 cells that normally don’t detach at significant rates. CONCLUSION: OSM promotes both EMT and tumor cell detachment in ER+ breast cancer cells. Yet, CD44 knockdown did not affect OSM-induced EMT in these cells, while independently decreasing OSM-induced cell detachment. These results suggest that regulation of CD44 by OSM is important for at least part of the metastatic cascade in ER+ breast cancer.
format Online
Article
Text
id pubmed-6700398
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67003982019-09-06 OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition Covert, Hunter Mellor, Liliana F Wolf, Cody L Ankenbrandt, Nicole Emathinger, Jacqueline M Tawara, Ken Oxford, Julie Thom Jorcyk, Cheryl L Cancer Manag Res Original Research BACKGROUND: Hormone receptor status in human breast cancer cells is a strong indicator of the aggressiveness of a tumor. Triple negative breast cancers (TNBC) are aggressive, difficult to treat, and contribute to high incidences of metastasis by possessing characteristics such as increased tumor cell migration and a large presence of the transmembrane protein, cluster of differentiation 44 (CD44) on the cell membrane. Estrogen receptor-positive (ER+) cells are less aggressive and do not migrate until undergoing an epithelial-mesenchymal transition (EMT). METHODS: The relationship between EMT and CD44 during metastatic events is assessed by observing changes in EMT markers, tumor cell detachment, and migration following cytokine treatment on both parental and CD44 knockdown human breast tumor cells. RESULTS: ER+ T47D and MCF-7 human breast cancer cells treated with OSM demonstrate increased CD44 expression and CD44 cleavage. Conversely, ER- MDA-MB-231 human breast cancer cells do not show a change in CD44 expression nor undergo EMT in the presence of OSM. In ER+ cells, knockdown expression of CD44 by shRNA did not prevent EMT but did change metastatic processes such as cellular detachment and migration. OSM-induced migration was decreased in both ER+ and ER- cells with shCD44 cells compared to control cells, while the promotion of tumor cell detachment by OSM was decreased in ER+ MCF7-shCD44 cells, as compared to control cells. Interestingly, OSM-induced detachment in ER- MDA-MB-231-shCD44 cells that normally don’t detach at significant rates. CONCLUSION: OSM promotes both EMT and tumor cell detachment in ER+ breast cancer cells. Yet, CD44 knockdown did not affect OSM-induced EMT in these cells, while independently decreasing OSM-induced cell detachment. These results suggest that regulation of CD44 by OSM is important for at least part of the metastatic cascade in ER+ breast cancer. Dove 2019-08-15 /pmc/articles/PMC6700398/ /pubmed/31496817 http://dx.doi.org/10.2147/CMAR.S208721 Text en © 2019 Covert et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Covert, Hunter
Mellor, Liliana F
Wolf, Cody L
Ankenbrandt, Nicole
Emathinger, Jacqueline M
Tawara, Ken
Oxford, Julie Thom
Jorcyk, Cheryl L
OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title_full OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title_fullStr OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title_full_unstemmed OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title_short OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
title_sort osm-induced cd44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700398/
https://www.ncbi.nlm.nih.gov/pubmed/31496817
http://dx.doi.org/10.2147/CMAR.S208721
work_keys_str_mv AT coverthunter osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT mellorlilianaf osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT wolfcodyl osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT ankenbrandtnicole osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT emathingerjacquelinem osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT tawaraken osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT oxfordjuliethom osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition
AT jorcykcheryll osminducedcd44contributestobreastcancermetastaticpotentialthroughcelldetachmentbutnotepithelialmesenchymaltransition